For example, future studies with castration-resistant prostate cancer patients will consider AR-V7 mutation as a target.38 However, since CTCs are rare, a significant enrichment and sample integrity is required to adapt to conventional analytical techniques. The gene discussed is AR; the disease is prostate carcinoma.